All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On October 16, 2023, it was announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion for zanubrutinib, a Bruton’s tyrosine kinase inhibitor, plus obinutuzumab for the treatment of adult patients with relapsed/refractory follicular lymphoma who have received at least two prior lines of systemic therapy.1 This recommendation was based on positive data from the pivotal phase II ROSEWOOD trial (NCT03332017).1
ROSEWOOD is an ongoing global, phase II study investigating zanubrutinib plus obinutuzumab compared with obinutuzumab alone in 217 adult patients with relapsed/refractory follicular lymphoma who received at least two prior lines of systemic therapy. At a median follow-up of 20 months, the overall response rate was 69% versus 45.8% in the zanubrutinib plus obinutuzumab and obinutuzumab monotherapy arms, respectively (p = 0.0012); and treatment was well-tolerated.1
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox